干细胞驱动的白血病中的代谢:造血与免疫之间的平行关系
本文综述白血病如何重塑微环境并重编程代谢,重点关注治疗抵抗性干细胞。通过对比髓系白血病干细胞与造血及免疫细胞功能所需的代谢重编程,突出其共享的代谢特征,并探讨在抗癌代谢抑制剂及抗癌免疫治疗背景下的关键考量。
要点
- 白血病干细胞与造血及免疫细胞共享多个代谢特征,影响代谢抑制剂和免疫治疗策略。
- 癌症代谢具有可塑性,不仅依赖糖酵解上调,还涉及多种通路以应对 extrinsic 挑战。
- 白血病细胞可修饰周围微环境,在疾病起始、维持和转移中促进治疗抵抗。
核心结论
- 白血病干细胞与造血及免疫细胞在代谢重编程上存在共享特征,这在考虑抗癌代谢抑制剂尤其抗癌免疫治疗时是关键考量。
研究设计与样本
- 综述性研究,旨在对关键代谢通路进行全局性、非穷尽性概述。
主要发现
- 癌症代谢不再被认为仅由糖酵解上调驱动,而是包含多种通路,在外源性挑战下具有高度可塑性。
- 癌细胞可在疾病起始、维持和转移过程中修饰周围微环境,从而促进治疗抵抗。
- 白血病是干细胞驱动癌症的范式模型,本综述关注白血病如何重塑微环境并重编程代谢,尤其关注治疗抵抗性干细胞。
- 通过对比髓系白血病干细胞与造血及免疫细胞功能所需的代谢重编程,突出其共享的代谢特征。
- 还探讨了在白血病中尚未研究但在实体癌转移及与新微环境相互作用中关键的代谢通路。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our understanding of cancer metabolism spans from its role in cellular energetics and supplying the building blocks necessary for proliferation, to maintaining cellular redox and regulating the cellular epigenome and transcriptome. Cancer metabolism, once thought to be solely driven by upregulated glycolysis, is now known to comprise multiple pathways with great plasticity in response to extrinsic challenges. Furthermore, cancer cells can modify their surrounding niche during disease initiation, maintenance, and metastasis, thereby contributing to therapy resistance. Leukemia is a paradigm model of stem cell-driven cancer. In this study, we review how leukemia remodels the niche and rewires its metabolism, with particular attention paid to therapy-resistant stem cells. Specifically, we aim to give a global, nonexhaustive overview of key metabolic pathways. By contrasting the metabolic rewiring required by myeloid-leukemic stem cells with that required for hematopoiesis and immune cell function, we highlight the metabolic features they share. This is a critical consideration when contemplating anticancer metabolic inhibitor options, especially in the context of anticancer immune therapies. Finally, we examine pathways that have not been studied in leukemia but are critical in solid cancers in the context of metastasis and interaction with new niches. These studies also offer detailed mechanisms that are yet to be investigated in leukemia. Given that cancer (and normal) cells can meet their energy requirements by not only upregulating metabolic pathways but also utilizing systemically available substrates, we aim to inform how interlinked these metabolic pathways are, both within leukemic cells and between cancer cells and their niche.
引用
- Rattigan KM, Zarou MM, Helgason GV, et al. Metabolism in stem cell-driven leukemia: parallels between hematopoiesis and immunity. Blood. 2023. PMID: 36634302. doi:10.1182/blood.2022018258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。